精神病中内源性大麻素系统紊乱的测量:系统综述与荟萃分析
该系统综述与荟萃分析纳入18项研究,评估精神病患者血液和脑脊液中内源性大麻素系统标志物的改变。结果显示患者脑脊液和血液中anandamide水平及外周免疫细胞1型大麻素受体表达显著高于健康对照,且高内源性大麻素张力见于疾病早期并与症状严重程度负相关、成功治疗后正常化。
要点
- 精神病患者脑脊液和血液anandamide水平显著高于健康对照。
- 患者外周免疫细胞1型大麻素受体表达显著升高。
- 高内源性大麻素张力见于早期未用药患者并与症状严重程度负相关。
核心结论
- 精神病患者血液和脑脊液中内源性大麻素系统标志物存在可测量的改变,可作为潜在生物标志物。
研究设计与样本
- 系统综述与荟萃分析,检索Web of Science和PubMed自建库至2018年6月13日,纳入18项报告精神病患者与健康对照血液或脑脊液内源性大麻素系统指标的原始研究。
主要发现
- 5项研究(226例患者、385例对照)显示患者脑脊液anandamide浓度显著高于对照(SMD 0.97,95%CI 0.67-1.26,P<.001,I2=54.8%)。
- 9项研究(344例患者、411例对照)显示患者血液anandamide水平显著高于对照(SMD 0.55,95%CI 0.05-1.04,P=.03,I2=89.6%)。
- 3项研究(88例患者、179例对照)显示患者外周免疫细胞1型大麻素受体表达显著高于对照(SMD 0.57,95%CI 0.31-0.84,P<.001,I2=0%)。
- 高内源性大麻素张力见于疾病早期未用药或未接触抗精神病药个体,与症状严重程度呈负相关,成功治疗后正常化。
关键数值与推荐
- 脑脊液anandamide升高:SMD 0.97(95%CI 0.67-1.26,P<.001,I2=54.8%)。
- 血液anandamide升高:SMD 0.55(95%CI 0.05-1.04,P=.03,I2=89.6%)。
- 外周免疫细胞1型大麻素受体表达升高:SMD 0.57(95%CI 0.31-0.84,P<.001,I2=0%)。
临床怎么用
- 血液和脑脊液内源性大麻素系统标志物有望作为精神病临床相关生物标志物进行检测。
- 解读标志物时需考虑大麻使用等重要混杂变量,部分研究未校正。
局限性
- 研究间方法学异质性中至高,部分研究未校正大麻使用等重要变量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The endocannabinoid system (ECS) is a lipid-based endogenous signaling system. Its relevance to psychosis is through the association between cannabis use and the onset and course of illness and through the antipsychotic properties of cannabidiol, a potential ECS enhancer. OBJECTIVE: To conduct a systematic review and meta-analysis of the blood and cerebrospinal fluid (CSF) measures of the ECS in psychotic disorders. DATA SOURCES: Web of Science and PubMed were searched from inception through June 13, 2018. The articles identified were reviewed, as were citations to previous publications and the reference lists of retrieved articles. STUDY SELECTION: Original articles were included that reported blood or CSF measures of ECS activity in patients with psychotic illnesses and in healthy controls. DATA EXTRACTION AND SYNTHESIS: PRISMA guidelines, independent extraction by multiple observers, and random-effects meta-analysis were used. Heterogeneity was assessed with the I2 index. Sensitivity analyses tested the robustness of the results. MAIN OUTCOMES AND MEASURES: The clinical relevance of ECS modifications in psychotic disorders was investigated by (1) a quantitative synthesis of the differences in blood and CSF markers of the ECS between patients and healthy controls, and (2) a qualitative synthesis of the association of these markers with symptom severity, stage of illness, and response to treatment. RESULTS: A total of 18 studies were included. Three individual meta-analyses were performed to identify the differences in ECS markers between people with schizophrenia and healthy controls. Five studies, including 226 patients and 385 controls, reported significantly higher concentrations of anandamide in the CSF of patients than controls (standardized mean difference [SMD], 0.97; 95% CI, 0.67-1.26; P < .001; I2 = 54.8%). In 9 studies, with 344 patients and 411 controls, significantly higher anandamide levels in blood were found in patients, compared with controls (SMD, 0.55; 95% CI, 0.05-1.04; P = .03; I2 = 89.6%). In 3 studies, involving 88 patients and 179 controls, a significantly higher expression of type 1 cannabinoid receptors on peripheral immune cells was reported in patients compared with controls (SMD, 0.57; 95% CI, 0.31-0.84; P < .001; I2 = 0%). Higher ECS tone was found at an early stage of illness in individuals who were antipsychotic naïve or free, and it had an inverse association with symptom severity and was normalized after successful treatment. Moderate to high level of heterogeneity in methods was found between studies. CONCLUSIONS AND RELEVANCE: Testing clinically relevant markers of the ECS in the blood and CSF of people with psychotic illness appears possible, and these markers provide useful biomarkers for the psychotic disorder; however, not all studies accounted for important variables, such as cannabis use. TRIAL REGISTRATION: PROSPERO identifier: CRD42018099863.
引用
- Minichino A, Senior M, Brondino N, et al. Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019. PMID: 31166595. doi:10.1001/jamapsychiatry.2019.0970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。